冈比亚2022-2024年母婴结局前瞻性妊娠监测
在冈比亚西部三个产前保健机构开展前瞻性观察监测,纳入5099名孕妇,记录4680次分娩,旨在估算与母体免疫接种安全监测相关的特定不良事件背景发生率。结果显示孕产妇死亡率为1.3/1000例分娩,死产率为21.8/1000活产,新生儿死亡率为15.6/1000活产,并报告了早产、低出生体重及严重先天畸形数。
要点
- 建立基于产前保健的妊娠登记可估算疫苗安全监测所需的背景发生率。
- 孕产妇死亡率1.3/1000例分娩,死产率21.8/1000活产,新生儿死亡率15.6/1000活产。
- 加强临床记录、诊断能力和疫苗接种史核实可提升结局分类质量。
核心结论
- 基于常规产前保健的监测可生成与母体免疫接种安全监测相关的特定母婴不良结局的站点特异性背景发生率。
研究设计与样本
- 前瞻性观察监测,2022年8月至2024年8月在冈比亚西部三个高量产前保健机构开展,纳入18岁及以上孕妇并随访至产后4-6周。
- 共纳入5099名孕妇,记录4680次分娩,获得4775名婴儿,其中活产4671名,死产104名。
主要发现
- 孕产妇死亡6例,孕产妇死亡率为1.3/1000例分娩(95%CI:0.5-2.7)。
- 死产率为21.8/1000活产(95%CI:17.8-26.3),新生儿死亡率为15.6/1000活产(95%CI:12.3-19.6)。
- 记录到398例早产、277例低出生体重儿和2例严重外部结构先天畸形。
- 419名(8%)参与者退出或失访。
临床怎么用
- 可利用产前保健机构建立的妊娠登记平台,估算与母体免疫接种安全监测相关的特定不良事件背景发生率。
- 应加强临床记录、诊断能力和疫苗接种史核实,以提高结局分类的准确性及监测平台的效用。
局限性
- 419名(8%)参与者退出或失访可能影响结局 ascertainment。
- 诊断确定性依据GAIA定义评估,但原文未报告各结局的确诊比例。
- 研究仅覆盖冈比亚西部三个产前保健机构,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reliable background estimates of adverse maternal and neonatal outcomes are needed to interpret safety signals as maternal vaccines are introduced but remain limited in many African settings. We established facility-based pregnancy registries in The Gambia to estimate site-specific background rates of selected adverse events of special interest (AESIs) relevant to maternal immunization safety monitoring. METHODS: We conducted prospective observational surveillance from August 2022 to August 2024 at three high-volume antenatal care facilities in the Western Region of The Gambia. Pregnant women aged 18 years or older were enrolled during routine antenatal care and followed through delivery to the 4-6-week postnatal visit. Selected AESIs were ascertained irrespective of vaccination status and delivery location, using routinely available clinical records. Diagnostic certainty was assessed using Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) definitions. Outcome-specific rates were calculated with 95% confidence intervals (CIs). RESULTS: Among 5099 enrolled women, 419 (8%) discontinued participation or were lost to follow-up. We recorded 4680 deliveries resulting in 4775 infants, including 4671 live births and 104 stillbirths. Six maternal deaths were recorded, corresponding to a maternal mortality rate of 1.3 per 1000 births (95% CI: 0.5-2.7). Stillbirth and neonatal mortality rates were 21.8 (17.8-26.3) and 15.6 (12.3-19.6) per 1000 live births, respectively. There were 398 preterm births, 277 infants with low birth weight and two babies with major external structural congenital anomalies. CONCLUSIONS: Surveillance embedded in routine antenatal care generated site-specific background rates of selected adverse maternal and neonatal outcomes relevant to maternal immunization safety monitoring. Strengthening clinical documentation, diagnostic capacity, and vaccination history ascertainment could improve outcome classification and the utility of these platforms for future safety monitoring.
引用
- Okomo U, Longley AT, Nkereuwem O, et al. Maternal and neonatal outcomes in The Gambia, 2022-2024: prospective pregnancy surveillance to strengthen maternal immunization safety monitoring. Vaccine. 2026. PMID: 42858678. doi:10.1016/j.vaccine.2026.129235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。